ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
AbCellera Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.93+0.13 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-289.0%−355.9 pts over 5 years
Net margin
-194.9%−245.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +160.6% | -46.3% | -20.3% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 28.3% | -14.5% | |
| Return on assets | – | – | -10.8% | |
| Current ratio | – | 7.86 | 11.32 | |
| Capex to revenue | – | 4.1% | 56.9% | |
| Diluted shares | – | 263M | 299M |
Where the cash went
Fiscal 2021 to 2025, five years combined
AbCellera Biologics generated $805.67M from operations and spent $327.23M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$805.67M
Used
$327.23M
Capital expenditure$327.23M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-194.9%
×Asset turnover0.06×
×Equity multiplier1.34×
=Return on equity, FY2025-14.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -194.9% | 0.06× | 1.34× | -14.5% |
| FY2024 | -564.8% | 0.02× | 1.29× | -14.7% |
| FY2023 | -385.0% | 0.03× | 1.27× | -12.3% |
| FY2022 | 32.7% | 0.34× | 1.27× | 14.0% |
| FY2021 | 40.9% | 0.32× | 1.25× | 16.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$146.41M
- Cash generatingOperating cash flow above zero-$131.30M
- Return on assets improvedROA up on the prior year-10.9% → -10.8%
- Earnings backed by cashOperating cash flow above net income-$131.30M vs -$146.41M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.81 → 11.32
- No dilutionShare count did not rise294M → 299M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.06